Publicaciones en colaboración con investigadores/as de Weill Cornell Medical College in Qatar (24)

2024

  1. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3

  2. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Annals of Oncology

  3. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4

2021

  1. Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT/ KEYNOTE-202 trial

    Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5020-5027

  2. The importance of low-dose CT screening to identify emphysema in asymptomatic participants with and without a prior diagnosis of COPD

    Clinical Imaging, Vol. 78, pp. 136-141

2020

  1. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1

  2. Key components of a hepatobiliary surgery curriculum for general surgery residents: results of the FULCRUM International Delphi consensus

    HPB, Vol. 22, Núm. 10, pp. 1429-1441

2019

  1. Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis

    Clinical Cancer Research, Vol. 25, Núm. 15, pp. 4663-4673

  2. Use of machine-learning algorithms in intensified preoperative therapy of pancreatic cancer to predict individual risk of relapse

    Cancers, Vol. 11, Núm. 5

2018

  1. Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program

    Annals of Oncology, Vol. 29, Núm. 2, pp. 405-417

2017

  1. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

    British Journal of Haematology, Vol. 177, Núm. 3, pp. 404-413

  2. European society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery

    International Journal of Gynecological Cancer, Vol. 27, Núm. 7, pp. 1534-1542

  3. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study

    Leukemia, Vol. 31, Núm. 11, pp. 2443-2448

2016

  1. European society of gynaecologic oncology quality indicators for advanced ovarian cancer surgery

    International Journal of Gynecological Cancer, Vol. 26, Núm. 7, pp. 1354-1363

  2. Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patientswith relapsed multiple myeloma

    Journal of Clinical Oncology, Vol. 34, Núm. 32, pp. 3921-3930

  3. Impact of surgery for stage IA non-smallcell lung cancer on patient quality of life

    Journal of Community and Supportive Oncology, Vol. 14, Núm. 1, pp. 37-44

  4. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2015

  1. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma

    New England Journal of Medicine, Vol. 372, Núm. 2, pp. 142-152

  2. Recurrent venous thromboembolism in anticoagulated patients with cancer: Management and short-term prognosis

    Journal of Thrombosis and Haemostasis, Vol. 13, Núm. 6, pp. 1010-1018

2014

  1. Classification of current anticancer immunotherapies

    Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508